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Prostate cancer is the most commonly diagnosed cancer
among men worldwide. Androgen deprivation therapy has
been a well established treatment for prostate cancer and
improves disease-free survival in combination with radia-
tion therapy in patients with locally advanced disease, but
has been associated with bone loss and increased fracture
risk. Fractures are an important contributor to morbidity
associated with androgen deprivation therapy. Existing
therapies have shown prevention of bone loss, but have
yet to demonstrate reduction in fractures. Denosumab, a
human monoclonal antibody that inhibits receptor activator
for nuclear factor-κB ligand, impacts osteoclasts formation
and survival, and has been shown to increase bone density
in postmenopausal osteoporosis and other hormone depri-
vation states.
Aims
The study was designed to examine whether administration
of denosumab in men with nonmetastatic prostate cancer
would affect bone mineral density and rates of fracture in
the vertebral spine and hip in a randomized, double-blind,
multicenter, placebo-controlled trial.
Methods
Patients with advanced local prostate cancer who were
expected to be on androgen deprivation therapy (bilateral
orchiectomy or gonadotropin-releasing hormone-agonist
therapy) for at least 12 months of the study period were
considered for inclusion in the trial. If under 70 years of age,
T-score at the lumbar spine, total hip, or femoral neck had to
be less than −1.0 at baseline or they must have had a previous
osteoporotic fracture. They could not have taken an oral
bisphosphonate within 1 year prior to entering the trial or ever
had exposure to an intravenous bisphosphonate. A total of 734
patients were assigned to each group and all were instructed to
take appropriate amounts of calcium and vitamin D. The
primary end point was percent change in bone mineral density
of the lumbar spine at 24 months. Secondary end points
included percent change in bone mineral density at 36 months
in the vertebral spine, percent change in the total hip and
femoral neck at 24 and 36 months, incidence of newly
diagnosed vertebral fracture at 36 months, fracture at any site,
time to first fracture, and safety events. The study was
originally intended to last 24 months but was extended to
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36 months specifically to further examine the fracture
prevention end point.
Results
A total of 912 (62%) of 1468 patients completed the 36-month
study, with the primary reason for discontinuation being
withdrawal of consent when the blinded period was extended
from 24 to 36months. A similar number discontinued study in
the placebo and treatment groups. Mean age was 75 years, and
most patients had been on androgen deprivation therapy for
greater than 6 months at initiation of study. Increased bone
mineral density was noted at all sites. The primary end point—
change in bone density at the lumbar spine at 24months—was
achieved, increasing 5.6% in the denosumab group versus
−1.0% in the placebo group (P<0.001). Changes in bone
mineral density in the lumbar spine were statistically
significantly different as early as 1 month on therapy at the
lumbar spine. At all other sites (total hip, femoral neck, distal
third of radius, and total body), statistically significant
increases in bone density on denosumab when compared
with placebo were observed. There was no difference in
various predetermined subgroups that were analyzed.
Denosumab-treated patients had decreases in vertebral
fractures observed at 12, 24, and 36 months. The 36-
month cumulative incidence of fracture was 3.9% in
placebo-versus 1.5% in denosumab-treated patients (CI,
0.19–0.78; P=0.006). Fracture at any site was diminished
but did not reach statistical significance (P=0.10). No
difference in time to first fracture was noted. Bone turnover
markers decreased significantly on denosumab when com-
pared with placebo. Cataracts appeared more prevalent in the
denosumab group. Serious infections were noted in 5.9% in
the denosumab patients compared with 4.6% on placebo. A
total of 6% of patients died in each group during the study.
No cases of delayed healing of nonvertberal fractures or
osteonecrosis of the jaw were reported.
Discussion
This is the first trial to demonstrate reduction in vertebral
fracture in men on androgen deprivation therapy with an
antiresorptive agent. Several studies have shown signif-
icant increases in bone density, but were not powered or
failed to demonstrate fracture efficacy [1–5]. This trial
was not powered to answer the question of nonvertebral
fractures, although the data suggested a trend to reduction
in all fractures. In addition, the effects in terms of bone
mineral density were seen early on, as soon as 1 month on
therapy, and although time to first fracture was not
reduced, the small number of patients who fractured in
the first month on denosumab (only two) may have
impacted that analysis. There were no concerning safety
signals noted, specifically no significant increased risk of
infection and no cases of osteonecrosis, which has
reportedly been seen in higher incidence in the cancer
patient population on bisphosphonates.
The study did not examine men with metastatic disease
who might be at even higher risk for fracture with androgen
therapy, although another recently published study sug-
gested that use of denosumab reduced the rate of skeletal-
related events in patients with metastatic disease, even if
they had already failed a bisphosphonate [6]. Although the
rate of bone loss and the incidence of vertebral fracture in
men on androgen deprivation therapy for prostate cancer are
not well characterized, bone loss in this group is universally
recognized. No approved therapy has been established for
the treatment of bone loss in men with prostate cancer. No
direct comparison with other treatments, such as bisphosph-
onates of selective estrogen receptor modulators, has been
performed; thus, determining which therapy is most effective
cannot be concluded from this trial.
Comments
Denosumab is the first drug shown to reduce vertebral
fractures in men on androgen deprivation therapy for
prostate cancer. Effects on bone mineral density are seen
very early on, as soon as 1 month into therapy. With the
increasing incidence of prostate cancer, more frequent use
of androgen deprivation therapy, and increased longevity in
men with disease, twice-yearly administration of denosu-
mab appears to be a safe and effective methodology of
preventing one the most common morbidities seen in men
with prostate cancer.
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